SI-BONE opened lower at $24.88, compared with its previous close of $24.94. In the last trading session, the stock traded between $24.00 and $25.07. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in SI-BONE is now worth
$ 108.20
Giving a profit of
$ 8.20 (8.20%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.80 (-3.21%)
Day High
$25.07
Day Low
$24.00
Day Open
$24.88
Prev Close
$24.94
Volume
6,32,244
1W Return
-3.28%
1M Return
20.12%
3M Return
28.45%
6M Return
107.92%
1Y Return
32.49%
Fundamentals
Market Cap ($ Mn)
1,089
PE Ratio
-
PB Ratio
4.70
PEG Ratio
-
ROE
-11.06%
ROCE
-10.81%
EPS (TTM)
$-0.08
Investment Returns
1 Week
-3.28%
1 Month
20.12%
3 Months
28.45%
6 Months
107.92%
9 Months
58.39%
Financials
Quarterly
All values in $ Mn
48.6
Jun 25
48.7
Sep 25
56.3
Dec 25
52.6
Mar 26
56.0
Jun 26
55.7
Sep 26
Updates
4Nov
UBS maintains Buy on SI-BONE, raises price target to $26
UBS analyst Patrick Wood maintains a Buy rating on SI-BONE. Price target increased from $25 to $26. Rating status remains unchanged at Buy.
9 days ago
4Nov
TD Cowen maintains Buy on SI-BONE, lifts price target to $23
TD Cowen maintained a Buy rating on SI-BONE. Price target raised from $20 to $23. Analyst Mathew Blackman issued the update.
9 days ago
3Nov
SI-BONE Q3FY26 Results: Revenue up 15% to $55.7 million, EBITDA rises 32%
Worldwide revenue rose 15% YoY to $55.7 million, driven by 20% U.S. procedure volume growth. Adjusted EBITDA increased 32.4% to $3 million, outpacing revenue growth due to operating leverage. Net loss narrowed to $3.6 million from $4.6 million in the prior-year period. Reaffirmed FY26 revenue guidance of $231 million to $233 million, implying >20% growth in Q4. New Onyx product launch expands total addressable market to over 650,000 annual procedures.
10 days ago
20Oct
Si-Bone to report Q3 2026 financial results on November 2
Si-Bone Inc. will report Q3 2026 financial results on November 2, 2026. Conference call scheduled for 4:30 pm Eastern Time after market close. Company has supported over 150,000 procedures since 2009.
24 days ago
14Oct
Truist Securities raises SI-BONE price target to $25, maintains Buy
Truist Securities raised SI-BONE's price target from $23 to $25. Analyst Richard Newitter maintained a Buy rating on the stock. The update reflects a revised valuation outlook for SI-BONE.
29 days ago
29Sep
SI-BONE gets FDA clearance for iFuse Granite Onyx spine system
SI-BONE receives FDA 510(k) clearance for iFuse Granite Onyx System. First product addressing compromised bone outside the pelvis. Targets loosening in up to 27% of spinal fusion constructs. Expands market opportunity beyond sacroiliac joint fusion niche.
